drugset / Trial / NCT01734057

Summary

The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Rituximab for the treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional high-dose dexamethasone therapy.

Timeline

Start
2012-07
Primary completion
2013-07
Completion
2013-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 40 mg Intravenous
Subject Rituximab Monoclonal antibody 100 mg Intravenous
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Subcutaneous